AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30768673 — intervention group
Group type: COMPARATOR
Intervention: Outpatient cognitive behavioural therapy (6 sessions/6 weeks)
Number of subjects: 334
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-work scores at baseline
Number of subjects: 334
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-work scores (consistently low)
Number of subjects: 334
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-work scores (reduced)
Number of subjects: 334
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-work scores (increased or consistently high)
Number of subjects: 334
Study 30768673 — intervention group
Group type: EXPERIMENTAL
Intervention: FABQ-physical activity subscale
Number of subjects: 334
Study 27488830 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM Express Indirect Calorimeter
Number of subjects: 30
Study 27488830 — intervention group
Group type: EXPERIMENTAL
Intervention: QUARK RMR ICU Indirect Calorimeter
Number of subjects: 30
Study 25910800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ECG recordings over 2 weeks
Number of subjects: 7173
Study 25910800 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of OAC treatment
Number of subjects: 7173
Study 25910800 — intervention group
Group type: COMPARATOR
Intervention: Known AF without OAC treatment
Number of subjects: 7173
Study 25910800 — intervention group
Group type: COMPARATOR
Intervention: Total AF prevalence
Number of subjects: 7173
Study 25910800 — intervention group
Group type: COMPARATOR
Intervention: Screening program
Number of subjects: 7173
Study 24220161 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2173
Study 24220161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 2173
Study 24220161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2173
Study 24220161 — intervention group
Group type: COMPARATOR
Intervention: Combined vitamin A+zinc
Number of subjects: 2173
Study 21668975 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-P group (whey protein plus carbohydrate drink)
Number of subjects: 17
Study 21668975 — intervention group
Group type: COMPARATOR
Intervention: CO group (water)
Number of subjects: 17
Study 19507410 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 60
Study 19507410 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine solution
Number of subjects: 60
Study 17107615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin therapy (6,000 IU bolus followed by 250 IU/hour for four days)
Number of subjects: 33
Study 17107615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17107615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin therapy
Number of subjects: 33
Study 15033097 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention (3 sessions lasting approximately 1.5 hours each)
Number of subjects: 0
Study 15033097 — intervention group
Group type: COMPARATOR
Intervention: Minimum intervention (brief personal counselling for 3 to 5 minutes)
Number of subjects: 0
Study 11251525 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-elbow position (KE)
Number of subjects: 117
Study 11251525 — intervention group
Group type: COMPARATOR
Intervention: Left-lateral position (LL)
Number of subjects: 117
Study 10395119 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungolon (test)
Number of subjects: 18
Study 10395119 — intervention group
Group type: COMPARATOR
Intervention: Diflucan (reference)
Number of subjects: 18
Study 8895284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 50
Study 8895284 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 50
Study 1854075 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation rewarming
Number of subjects: 8
Study 1854075 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral rewarming
Number of subjects: 8
Study 1854075 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation rewarming and peripheral rewarming evaluated separately or in combination
Number of subjects: 8
Study 6889154 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfisoxazole at 500 mg twice a day
Number of subjects: 72
Study 6889154 — intervention group
Group type: EXPERIMENTAL
Intervention: pneumococcal immunization
Number of subjects: 72
Study 6889154 — intervention group
Group type: EXPERIMENTAL
Intervention: both pneumococcal vaccine and 500 mg sulfisoxazole twice daily
Number of subjects: 72
Study 6889154 — intervention group
Group type: COMPARATOR
Intervention: no routine medication
Number of subjects: 72
Study 6889154 — intervention group
Group type: COMPARATOR
Intervention: antihistamines whenever nasally congested
Number of subjects: 72
Study 30885256 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + physical exercise
Number of subjects: 70
Study 30885256 — intervention group
Group type: COMPARATOR
Intervention: CBT + telephone calls
Number of subjects: 70
Study 29395554 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=22)
Number of subjects: 43
Study 29395554 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 43
Study 26740092 — intervention group
Group type: COMPARATOR
Intervention: Teacher professional development intervention delivered partially via the Internet, including two workshops and implementation tasks over 6 months, followed by a booster period of 3 months with additional workshops and mentoring.
Number of subjects: 0
Study 24493368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 48
Study 24493368 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 48
Study 22127270 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg EGCG
Number of subjects: 0
Study 22127270 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study 19409341 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (HG) treatment started immediately with no other appliances used during the first 2 years
Number of subjects: 68
Study 19409341 — intervention group
Group type: COMPARATOR
Intervention: Control group with only minor interceptive procedures during the first 2 years
Number of subjects: 68
Study 17765616 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 60, mean daily dose of 46 +/- 9 mg)
Number of subjects: 120
Study 17765616 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (n = 60, mean daily dose of 93 +/- 11 mg)
Number of subjects: 120
Study 15124719 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue‐muscle training (20 minutes twice a day for 8 weeks)
Number of subjects: 67
Study 15124719 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 67
Study 12641016 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stent grafts
Number of subjects: 0
Study 12641016 — intervention group
Group type: COMPARATOR
Intervention: Conventional stents
Number of subjects: 0
Study 9849815 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) at a fixed daily dose of 8 microg/kg birthweight
Number of subjects: 200
Study 9849815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7853127 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR procedure using the resorbable synthetic material (experimental)
Number of subjects: 40
Study 7853127 — intervention group
Group type: COMPARATOR
Intervention: Mucoperiosteal flap debridement procedure without barrier placement (control)
Number of subjects: 40
Study 2596736 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline (6 mg/kg over fifteen minutes)
Number of subjects: 13
Study 2596736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31501133 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT‐ILE intervention (6.5 hours per day for 10 days, total 65 hours)
Number of subjects: 126
Study 31501133 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlisted for 26 weeks)
Number of subjects: 126
Study 28328148 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX (extended-release naltrexone)
Number of subjects: 168
Study 26350388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg/90 mg twice daily)
Number of subjects: 48
Study 26350388 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel (150 mg/day)
Number of subjects: 48
Study 23493898 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 18
Study 23493898 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS measures of cerebral oxygenation
Number of subjects: 18
Study 23493898 — intervention group
Group type: COMPARATOR
Intervention: Control group (neonate controls)
Number of subjects: 18
Study 22027321 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoPen 4
Number of subjects: 116
Study 22027321 — intervention group
Group type: COMPARATOR
Intervention: NovoPen 3
Number of subjects: 116
Study 19692680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg per day)
Number of subjects: 1217
Study 19692680 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (carboplatin dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute plus paclitaxel 200 mg per square meter of body-surface area)
Number of subjects: 1217
Study 19692680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 1217
Study 19692680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib in patients with EGFR mutation
Number of subjects: 1217
Study 19692680 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel in patients without EGFR mutation
Number of subjects: 1217
Study 19692680 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel
Number of subjects: 1217
Study 16467543 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (160 mg twice a day)
Number of subjects: 225
Study 16467543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15566590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategy with additional cytokine measurements
Number of subjects: 0
Study 15566590 — intervention group
Group type: COMPARATOR
Intervention: Routine sepsis work up
Number of subjects: 0
Study 11130223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by clinical pharmacists
Number of subjects: 208
Study 11130223 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 208
Study 9249645 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 9249645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8391686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid succession (5 sec apart)
Number of subjects: 8
Study 8391686 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second intervals and shaking MDI between two rapid activations
Number of subjects: 8
Study 8391686 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-second intervals and shaking between each activation
Number of subjects: 8
Study 8391686 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second intervals and shaking between each activation
Number of subjects: 8
Study 2952160 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 degrees head down position for 30 min post-operation
Number of subjects: 131
Study 2952160 — intervention group
Group type: COMPARATOR
Intervention: Flat position post-operation (control group)
Number of subjects: 131
Study 2952160 — intervention group
Group type: EXPERIMENTAL
Intervention: Falope rings for sterilization
Number of subjects: 131
Study 2952160 — intervention group
Group type: COMPARATOR
Intervention: Hulka clip sterilization or diagnostic laparoscopy (control for Falope rings)
Number of subjects: 131
Study 2952160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 131
Study 30572544 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft non‐manipulative osteopathic techniques (1 session every 10 days for 30 days)
Number of subjects: 30
Study 30572544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study 27078181 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-awareness with identification
Number of subjects: 138
Study 27078181 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-awareness with disidentification
Number of subjects: 138
Study 27078181 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study 25704652 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (GL) 3mg/d + ketotifen 1mg twice daily
Number of subjects: 48
Study 25704652 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (GL) 3mg/d + ketotifen 1mg once daily
Number of subjects: 48
Study 25704652 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (GL) 3mg/d alone
Number of subjects: 48
Study 23143410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (20 cc)
Number of subjects: 223
Study 23143410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 cc 5% dextrose solution)
Number of subjects: 223
Study 20966212 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual-motor intervention (2 times per week for 8 weeks)
Number of subjects: 50
Study 20966212 — intervention group
Group type: COMPARATOR
Intervention: Home program (1 time per week for 8 weeks)
Number of subjects: 50
Study 19043129 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented trabecular metal tibial components
Number of subjects: 41
Study 19043129 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial components
Number of subjects: 41
Study 15924982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone
Number of subjects: 534
Study 15924982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 534
Study 12486284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocretin‐1 (hcrt‐1) measurement
Number of subjects: 0
Study 12486284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocretin‐2 (hcrt‐2) measurement
Number of subjects: 0
Study 9892449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline and IPT
Number of subjects: 187
Study 9892449 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline and medication clinic visits (placebo)
Number of subjects: 187
Study 9892449 — intervention group
Group type: COMPARATOR
Intervention: IPT and placebo
Number of subjects: 187
Study 9892449 — intervention group
Group type: COMPARATOR
Intervention: Placebo and medication clinic visits
Number of subjects: 187
Study 9892449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with nortriptyline and IPT
Number of subjects: 187
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance muscle strength training for 12 weeks
Number of subjects: 24
Study 8670319 — intervention group
Group type: COMPARATOR
Intervention: Swimming-only control group
Number of subjects: 24
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate treatment
Number of subjects: 24
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with tumor necrosis factor alpha (TNF alpha)
Number of subjects: 24
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone
Number of subjects: 24
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with plasma glucagon levels
Number of subjects: 24
Study 8670319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone and glucagon
Number of subjects: 24
Study 2070058 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week
Number of subjects: 59
Study 2070058 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon-alpha-2a (rIFN-alpha-2a) therapy
Number of subjects: 59
Study 6225762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 41
Study 29105879 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help version (n=146)
Number of subjects: 578
Study 29105879 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided intervention with adherence-focused guidance by eCoaches (n=144)
Number of subjects: 578
Study 29105879 — intervention group
Group type: COMPARATOR
Intervention: Control group on a waiting list with full access to usual care (n=144)
Number of subjects: 578
Study 29105879 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups (unguided and guided)
Number of subjects: 578
Study 28133385 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme with a treadmill with visual feedback function (n = 23)
Number of subjects: 46
Study 28133385 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 46
Study 24836312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (2403 mg per day)
Number of subjects: 555
Study 24836312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 22614874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin (75 mg/day + 100 mg/day)
Number of subjects: 57
Study 22614874 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 57
Study 19387817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually explicit video (n = 20)
Number of subjects: 79
Study 19387817 — intervention group
Group type: COMPARATOR
Intervention: Neutral video (n = 20)
Number of subjects: 79
Study 19387817 — intervention group
Group type: COMPARATOR
Intervention: Humor video (n = 19)
Number of subjects: 79
Study 19387817 — intervention group
Group type: COMPARATOR
Intervention: Anxiety provoking video (n = 20)
Number of subjects: 79
Study 18269638 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp) thrice-daily regimen
Number of subjects: 604
Study 18269638 — intervention group
Group type: COMPARATOR
Intervention: Biphasic human insulin (BHI) 30 group
Number of subjects: 604
Study 15933797 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 28
Study 12689395 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.7F ureteral stent
Number of subjects: 46
Study 12689395 — intervention group
Group type: COMPARATOR
Intervention: 6F ureteral stent
Number of subjects: 46
Study 10773786 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100
Study 10773786 — intervention group
Group type: COMPARATOR
Intervention: Laparotomic cholecystectomy
Number of subjects: 100
Study 8823850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 72
Study 1448739 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (750 milligrams) prophylactic cefamandole delivered directly into the operative wound with local anesthesia
Number of subjects: 324
Study 1448739 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 324
Study 2410571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 24
Study 2410571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2410571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimulation with moderate pressure over a large area
Number of subjects: 24
Study 30289509 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 300
Study 30289509 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 300
Study 30142111 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Port vein grafts
Number of subjects: 117
Study 30142111 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn grafts
Number of subjects: 117
Study 30142111 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Port device
Number of subjects: 117
Study 26713321 — intervention group
Group type: EXPERIMENTAL
Intervention: Periorbital cooling
Number of subjects: 50
Study 26713321 — intervention group
Group type: COMPARATOR
Intervention: No cooling (control)
Number of subjects: 50
Study 25172603 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-BRT (30Gy/12 fractions)
Number of subjects: 64
Study 25172603 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT (50Gy/25 fractions)
Number of subjects: 64
Study 22138585 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 polyethylene glycol (PEG) drops
Number of subjects: 23
Study 22138585 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG drops
Number of subjects: 23
Study 22138585 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC drops
Number of subjects: 23
Study 22138585 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG and CMC drops
Number of subjects: 23
Study 22138585 — intervention group
Group type: COMPARATOR
Intervention: Control group (CMC, PVA, glycerine drops)
Number of subjects: 23
Study 19739124 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 8389
Study 19739124 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 8389
Study 17399621 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy (group A)
Number of subjects: 100
Study 16342903 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-BMA
Number of subjects: 10
Study 16342903 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 10
Study 16342903 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA
Number of subjects: 10
Study 16342903 — intervention group
Group type: COMPARATOR
Intervention: Control (non-contrast MRI)
Number of subjects: 10
Study 10704165 — intervention group
Group type: EXPERIMENTAL
Intervention: ACD CPR plus ITV
Number of subjects: 21
Study 10704165 — intervention group
Group type: COMPARATOR
Intervention: ACD CPR alone
Number of subjects: 21
Study 9129857 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide smoking cessation intervention
Number of subjects: 0
Study 9129857 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (control)
Number of subjects: 0
Study 8419612 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg/m2 nightly)
Number of subjects: 10